NCT06467435View on ClinicalTrials.gov

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

PHASE1RecruitingINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2027

Conditions

Thyroid Eye Disease

Interventions

DRUG

Kamuvudine-9

96 mg tablets taken twice a day for 24 weeks

DRUG

Kamuvudine-9

96 mg tablets taken once

Trial Locations (1)

40506

RECRUITING

University of Kentucky, Lexington

Sponsors

Collaborators (1)

Inflammasome Therapeutics

All Listed Sponsors

collaborator

Inflammasome Therapeutics

UNKNOWN

lead

Peter Timoney

OTHER